Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.
- Why Clinical Supply Risk Starts With Demand Signals
- A Year Of Separation: Which Advanced Modalities Are Built For Commercial Scale In 2026?
- New ISPE Framework Targets Uncertainty In Pharma's AI Deployment
- Disciplined CGT Will Win On 2026 Regulatory Flexibility
- In Vivo's Biggest Threat — Comparison To Old Models
- The 5-Layer Fix For AI Failure In Pharmaceutical Manufacturing
- Why Use Total Organic Carbon Analysis For Cleaning Validation?
- December 2025 — CDMO Opportunities And Threats Report
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Intuitive Bioprocess Scale-Up From Bench Scale To Pilot Scale
This study explores scaling a high-demand fed-batch process from bench to pilot scale, highlighting control parameter differences at 50L and 500L while maintaining consistent growth and product titers.
-
Comparing Sterility Testing Techniques
Is your sterility testing process hindering your product release? Discover how the right approach can streamline your process, reduce false positives, and ultimately save you time and money.
-
Why Choose Robotic Processing For Small Batch Aseptic Filling
Reducing human intervention in aseptic filling is critical for safety and cost efficiency. Learn why automation is essential for small-batch applications and how it’s transforming sterile drug manufacturing.
-
Simplify Process Scale-Up With An Innovative Single-Use Bioreactor
Consistent cell growth and protein yields from 5 L to 5,000 L show how a unified bioreactor design can simplify scale-up, reduce risk, and accelerate upstream process development in bioproduction.
-
Guide To Seeding, Expanding, And Harvesting Stem Cells
Investigate important considerations for working with three different stem cell types: mesenchymal stem/stromal cells, induced pluripotent stem cells, and neural stem cells.
-
The Application Of The Species-Specific Liver-Chip In Predicting Hepatoxicity
An evaluation of 150 drug candidates causing adverse events in humans revealed testing in rats and dogs predicted only 71% of toxicities in humans. Discover a solution to this translational challenge.
-
Revolutionizing Viral Infectious Disease Research And Drug Discovery
Learn how Organ-Chips are being used to rapidly identify promising treatments, investigate virus evolution, and analyze how mechanical forces influence the innate immune response to viral infections.
-
The Complete Flow Cytometry Guide
This guide covers the fundamentals of flow cytometry, aiming to help you better understand how it works, when it is most valuable, and how to conduct an experiment.
-
Streamline Your mAb Manufacturing With Strategic Development And CDMO Compatibility
Though the journey to mAb development begins at lab scale, for clinical trials and commercial distribution, a production process must be streamlined and scalable to 2,000 L production and above.
-
Large Scale Purification Of Oligonucleotides With IEX
As oligonucleotide-based drugs gain momentum in therapeutic development, refining their manufacturing processes through solutions like ion exchange chromatography (IEX) becomes crucial.
NEWSLETTER ARCHIVE
- 02.12.26 -- Why Your MVP And Its Evolution Matters To Manufacturing
- 02.11.26 -- Breakthroughs In Cell Research & Automation
- 02.11.26 -- Disciplined CGT Will Win On 2026 Regulatory Flexibility
- 02.10.26 -- The Future Of Pharma Manufacturing Starts With Digitalization
- 02.10.26 -- STREAM Edition: 2026 Regulatory Roadmap: Get Set Up For Success
- Disciplined CGT Will Win On 2026 Regulatory Flexibility
- ARM's Tim Hunt On Expanding Patient Access, Smarter Regulation, And A More Sustainable Market In 2026
- Global Shifts And Strategic Resilience Will Shape CGT In 2026
- Why Efficiency In Multi-Modal CGT Manufacturing Is About Execution, Not Just Cost
- CSL's HEMGENIX Shows Durable Benefit, A New Future For Gene Therapy in Hemophilia B
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections